Held by 2 specialist biotech funds
**Signal Note: Deerfield Entry into TNDM** Deerfield Management's $573K initiation in Tandem Diabetes Care suggests conviction in the automated insulin delivery market, likely driven by recent or anticipated FDA approvals/label expansions for their t:slim X2 platform or competitive positioning against Medtronic's dominance. The entry size is modest but notable given Deerfield's selective healthcare thesis, signaling confidence in TNDM's ability to capture share in the growing closed-loop diabetes management space, which has seen accelerating adoption post-2020 FDA approvals.